Pfizer and BioNTech starts clinical trial for Omicron vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Omicron vaccine trial starts

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.

The study will evaluate the vaccine for safety, tolerability and the level of the immune response, as both a primary series and a booster dose, in up to 1,420 healthy adults ages 18 to 55.

The study is broken up into three groups:
Participants in the first cohort have received two doses of the current Pfizer Covid-19 vaccine at least 90 to 180 daysbefore the study. They will receive one or two doses of the Omicron-specific vaccine. After the Omicron wave, here's what experts say could come next in 2022.

Participants in the second cohort have received three doses of the current Pfizer Covid-19 vaccine at least 90 to 180 days prior to the study. They will receive one dose of the current Pfizer Covid-19 vaccine or the Omicron-specific vaccine.
Participants in the third cohort have not received any Covid-19 vaccine. They will receive three doses of the Omicron-specific vaccine.

The Omicron-specific vaccine will be administered as a 30-microgram dose, the same as the current vaccine.
"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer Senior Vice President and Head of Vaccine Research and Development Kathrin Jansen said in the release.

For Full story

https://edition.cnn.com/2022/01/25/health/pfizer-biontech-omicron-vaccine-trial/index.html 

Tags : #Pfizer #BioNTech #Omicron #OmicronVaccine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Medicolegal Risks in TelemedicineJune 24, 2025
Digital Mental Health Clinics in Tier-2 CitiesJune 24, 2025
AssisTech Foundation Hosts Inclusive Job Festival for Persons with DisabilitiesJune 23, 2025
Travel with Ease: Why Congestion Patches Are the Smart Traveler’s Secret WeaponJune 23, 2025
Paper-Tech Platform Paper Arizona Hits ₹100 Cr Annual Revenue Milestone, Eyes IPO Listing in 2026June 23, 2025
Eat Better to enhance its Quick Commerce Operations with UnicommerceJune 23, 2025
Stahl Unveils Blacksmith Signature Cast Iron Tawas: A Classic Essential with a Modern Update for Timeless Indian KitchensJune 23, 2025
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsJune 23, 2025
Finding strength in struggle for gender equality and human rightsJune 23, 2025
CTS Speciality Hospital Brings Robotic Knee Surgery Ushering in a New Era of Joint CareJune 23, 2025
Air Quality & Cardiovascular Morbidity: The Missing LinkJune 23, 2025
Menstrual Product Tax Relief & Health AccessJune 23, 2025
Sports Medicine Goes Virtual via WearablesJune 23, 2025
The Silent Guardian: How Smart Pill Dispensers Bring Peace to Indian FamiliesJune 23, 2025
Low-Cost AI Diagnostics for Retinal DiseaseJune 23, 2025
Yoga Beyond Fitness: Olive Hospital Spreads Awareness on Its Preventive Health BenefitsJune 21, 2025
Medanta- The Medicity Underscores Commitment to Holistic Well-Being Through Large-Scale International Yoga Day CelebrationsJune 21, 2025
The Rise of Digital Symptom Checkers in IndiaJune 21, 2025
3-D Printed Prosthetics for Indian AmputeesJune 21, 2025
The Silent Drain: Why NAFLD is Hurting Middle Aged India's Health and WalletJune 21, 2025